Treatment gaps and mortality among patients with familial hypercholesterolemia and cardiovascular disease: a 4-year follow-up study

Zafrir B Jubran A Lavie G , et al. Clinical determinants and treatment gaps in familial hypercholesterolemia: data from a multi-ethnic regional health service. Eur J Prev Cardiol 2017; 24: 867–875.

Perez-Calahorra S Laclaustra M Marco-Benedí V , et al. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis 2019; 284: 245–252.

Parhofer KG. Lower diabetes rate in patients with familial hypercholesterolaemia: what is the link? Eur J Prev Cardiol. Epub ahead of print 13 February 2020. DOI: 10.1177/2047487320903158

Duell PB Gidding SS Andersen RL , et al. Longitudinal low-density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis 2019; 289: 85–93.

Lee S Akioyamen LE Aljenedil S , et al. Genetic testing for familial hypercholesterolemia: impact on diagnosis, treatment and cardiovascular risk. Eur J Prev Cardiol 2019; 26: 1262–1270.

Mach F Baigent C Catapano AL , et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188.

Krogh HW Mundal L Holven KB , et al. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur Heart J 2016; 37: 1398–1405.

Bianconi V Banach M Pirro M , et al. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc Med. Epub ahead of print 12 March 2020. DOI: 10.1016/j.tcm.2020.03.004

Khachadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med 1964; 37: 402–407.

Brown MS Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science 1974; 185: 61–63.